Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients

NCT02555813 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02555813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02555813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
May 8, 2015
Completion date
September 7, 2020
Enrollment
317 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer